25I-NBOMe

From PsychonautWiki
Jump to: navigation, search

Skull and crossbones darktextred2.png

25I-NBOMe can be fatal at heavy doses.[1]

It is strongly discouraged to take large amounts of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25I-NBOMe
25I-NBOMe
25I-NBOMe.svg
Chemical Nomenclature
Common names 25i-NBOMe, 25i, Cimbi-5
Substitutive name 2C-I-NBOMe
Systematic name 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold 50 - 200 µg
Light 200 - 500 µg
Common 500 - 700 µg
Strong 700 - 1000 µg
Heavy 25I-NBOMe can be fatal at heavy doses.[2]
Duration
Total 6 - 10 hours
Onset 15 - 120 minutes
Come up 30 - 120 minutes
Peak 2 - 4 hours
Offset 1 - 4 hours
After effects 3 - 6 days
Insufflated
Dosage
Threshold 50 - 200 µg
Light 200 - 500 µg
Common 500 - 700 µg
Strong 700+ µg
Heavy 25I-NBOMe can be fatal at heavy doses.[3]
Duration
Total 4 - 6 hours
Onset 5 - 10 minutes
Come up 10 - 30 minutes
Peak 60 - 120 minutes
Offset 120 - 180 minutes
After effects 1 - 7 days






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

25I-NBOMe (also known as 2C-I-NBOMe, Cimbi-5 and N-Bomb, although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel psychedelic substance of the phenethylamine chemical class that produces an array of visually-dominant and stimulating psychedelic effects when administered.

The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic 2C-I. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin.[4] It was further researched by a team at Purdue University led by David Nichols.[5] It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).[6][7]

It is worth noting that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.

Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans. It had no history of human use before being sold online as a designer drug in 2010.[citation needed]. It has been associated with many deaths and hospitalizations. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.

Chemistry

25I-NBOMe or 2C-I-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-I. 25I-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as an iodine atom attached to carbon R4. It differs from 2C-I structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. 25I-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25I-NBOMe has efficacy at the 5-HT2A receptor where it acts as an unusually potent and selective partial agonist.[8] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.[8] Contrary to popular belief, it is not a "full agonist", although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics.

The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.[9]

Ki-values[10][9]
Receptor Ki (nM) ±
5-HT2A 0.044
5-HT2C 2
5-HT6 73 12
μ-opioid 82 14
H1 189 35
5-HT2B 231 73
κ-opioid 288 50

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Transpersonal effects
Infinity4.svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it is potentially fatal at heavy dosages.[11] PsychonautWiki advises that due to 25I-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several deaths in the past year.[12]

This substance came to media attention in early 2012 after a cluster of seven non-fatal overdoses with the drug were reported in or around Richmond, Virginia.[13][14] As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States.[15] In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.[16]

A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.[17]

A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.[18]

A Brazilian 16-year-old died from overdose in April 2016.[citation needed]

The addition of 5-HTP can greatly increase the effects of 25i-NBOME and should be avoided.[citation needed]

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

25I-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25I-NBOMe is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back at baseline (in the absence of further consumption). 25I-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.

Dangerous interactions

Ambulance2.png

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal status

  • Australia: Possession, production and sale is illegal.[citation needed]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[20]
  • Canada: 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[21]
  • China - As of October 2015 25I-NBOMe is a controlled substance in China.[22]
  • Germany - Possession, production and sale is illegal.[23]
  • Israel: The drug was banned in 2012.[24]
  • Italy: In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.[25]
  • Latvia: 25I-NBOMe is a Schedule I controlled substance.[26]
  • New Zealand: 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.[27]
  • Romania: In 2011, Romania banned all psychoactive substances,[28] no matter what they really are.[29]
  • Russia: Possession, production and sale is illegal.[citation needed]
  • Sweden: 25I-NBOMe is classed as Schedule I.[30]
  • United Kingdom - 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[31]
  • United States: On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.[32]

See also

External links

Discussion

References

  1. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  2. "Fatalities / Deaths". Erowid. April 26 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  3. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  4. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
  5. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
  6. https://www.ncbi.nlm.nih.gov/pubmed/21174090
  7. http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V
  8. 8.0 8.1 Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090
  9. 9.0 9.1 High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904
  10. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21174090
  11. "Fatalities / Deaths". Erowid. April 26, 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  12. http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/
  13. "Kids overdosing on new drug. Laura Geller, WWBT NBC12, Feb 18, 2012 | http://www.nbc12.com/story/16964534/kids-overdosing-on-new-drug
  14. New street drug causing concern among medics. Vanessa Araiza, WBRC, Feb 28, 2012, | http://www.wsfa.com/story/16977573/new-street-drug-causing-concern-among-medics
  15. New drug N-bomb hits the street, terrifying parents, troubling cops | http://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327
  16. Breaking Bad: Digital Drug Sales, Analog Drug Deaths. Craig Malisow, Houston Press, March 13, 2013 | http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/
  17. 21-year-old dies after one drop of new synthetic drug at Voodoo Fest. Naomi Martin, NOLA, November 1, 2012 | http://www.nola.com/crime/index.ssf/2012/11/21-year-old_dies_after_one_dro.html#incart_m-rpt-2/
  18. New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/
  19. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  20. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  21. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  22. http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知
  23. BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  24. http://www.health.gov.il/LegislationLibrary/25574413.pdf
  25. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  26. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  27. http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576
  28. http://drogriporter.hu/node/2211
  29. http://www.dreptonline.ro/legislatie/legea_194_2011_comba
  30. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  31. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  32. http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml